Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Consolidated Net Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Consolidated Net Income for 11 consecutive years, with -$77.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Consolidated Net Income fell 218.7% to -$77.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$136.8 million, a 274.75% decrease, with the full-year FY2025 number at -$130.3 million, down 68.26% from a year prior.
  • Consolidated Net Income was -$77.4 million for Q4 2025 at Cartesian Therapeutics, down from -$19.5 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $15.0 million in Q2 2024 to a low of -$77.4 million in Q4 2025.
  • A 5-year average of -$12.3 million and a median of -$13.6 million in 2024 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 5505.67% in 2022, then crashed 700.58% in 2023.
  • Cartesian Therapeutics' Consolidated Net Income stood at $12.4 million in 2021, then crashed by 52.39% to $5.9 million in 2022, then plummeted by 700.58% to -$35.4 million in 2023, then surged by 31.41% to -$24.3 million in 2024, then tumbled by 218.7% to -$77.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Consolidated Net Income are -$77.4 million (Q4 2025), -$19.5 million (Q3 2025), and -$20.1 million (Q2 2025).